Richard Kefford

Research interests

Publications

• Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz011

• Whole-genome landscapes of major melanoma subtypes

  Nature · 2017 · https://doi.org/10.1038/nature22071

• Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1708539

• Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF -Mutant Melanoma

  Clinical Cancer Research · 2017 · https://doi.org/10.1158/1078-0432.ccr-16-2923

• Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2015.64.0391

• Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

  JAMA · 2016 · https://doi.org/10.1001/jama.2016.4059

• Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2016.67.2477

• Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

  European Journal of Cancer · 2015 · https://doi.org/10.1016/j.ejca.2015.08.022

• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

  The Lancet · 2014 · 10.1016/s0140-6736(14)60958-2

• BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

  Clinical Cancer Research · 2014 · https://doi.org/10.1158/1078-0432.ccr-13-3122

• Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma

  Nature Communications · 2014 · https://doi.org/10.1038/ncomms6694

• Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.44.6112

• Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.44.5585

• Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

  Cancer Discovery · 2013 · 10.1158/2159-8290.cd-13-0642

• Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

  New England Journal of Medicine · 2013 · 10.1056/nejmoa1305133

• Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1210093

• Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

  The Lancet · 2012 · 10.1016/s0140-6736(12)60398-5

• Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

  Nature Communications · 2012 · 10.1038/ncomms1727

• Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70431-x

• Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma

  The American Journal of Surgical Pathology · 2012 · https://doi.org/10.1097/pas.0b013e31826485c0

• Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1112302

• Genome-wide association study identifies three new melanoma susceptibility loci

  Nature Genetics · 2011 · https://doi.org/10.1038/ng.959

• A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma

  Nature · 2011 · https://doi.org/10.1038/nature10630

• Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3

  Nature Genetics · 2011 · https://doi.org/10.1038/ng.958

• Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2010.32.4327

• Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

  Clinical Cancer Research · 2011 · 10.1158/1078-0432.ccr-11-2479

• Sunbed use during adolescence and early adulthood is associated with increased risk of early‐onset melanoma

  International Journal of Cancer · 2010 · https://doi.org/10.1002/ijc.25576

• Genome-wide association study identifies three loci associated with melanoma risk

  Nature Genetics · 2009 · https://doi.org/10.1038/ng.411

• Common sequence variants on 20q11.22 confer melanoma susceptibility

  Nature Genetics · 2008 · https://doi.org/10.1038/ng.163

Current projects

No projects listed.